Atropos Health, a startup that utilizes real-world patient data to help doctors make informed decisions, has raised $33 million in a Series B funding round led by Valtruis. The company, which has a valuation of around $250 million, aims to provide evidence-based guidance for medical decisions that may not have been studied in traditional clinical trials. By analyzing millions of patient records, Atropos can generate statistical analyses in a matter of days, providing valuable insights for healthcare professionals.
The startup’s approach involves running separate queries on individual data piles, rather than creating one massive dataset, in what is known as a federated data model. This unique approach appealed to investors, including billionaire venture capital investor Jim Breyer, who joined Atropos’ seed round and board in 2020. Breyer recognized the challenges in sharing medical data across different providers and saw the potential for Atropos to improve patient outcomes by generating evidence-based recommendations for clinicians.
Atropos was founded by CEO Brigham Hyde, who recognized the limitations of traditional healthcare data aggregation methods. Rather than consolidating data into one central location, Atropos conducts analyses on each individual data source and combines the results in a meta-analysis. This allows the company to provide doctors and researchers with valuable insights based on real-world patient responses to different treatments, without compromising patient privacy or biasing results towards the entity with the most data.
One of Atropos’ recent studies involved analyzing the risk of complications for patients on GLP-1 agonists undergoing surgery. The analysis, based on over 13,000 patients with diabetes, found no evidence to support stopping the drugs before surgery. While some experts questioned the study’s methodology and sample size, Atropos continues to add new patient data and medications to its database in order to generate new evidence and provide more comprehensive insights for medical decision-making.
Atropos’ ultimate goal is to help clinicians make better decisions by leveraging real-world patient data to inform medical guidance. By analyzing millions of patient records and generating evidence-based recommendations, the company aims to improve patient outcomes and extend lives. With ongoing support from investors and strategic partners, Atropos is poised to continue its mission of revolutionizing healthcare decision-making through data-driven insights.
